WallStreetZenWallStreetZen

NASDAQ: INTS
Intensity Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for INTS

Based on 1 analyst offering 12 month price targets for Intensity Therapeutics Inc

Min Forecast
$8.50+2,572.96%
Avg Forecast
$8.50+2,572.96%
Max Forecast
$8.50+2,572.96%

Should I buy or sell INTS stock?

Based on 1 analyst offering ratings for Intensity Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their INTS stock forecasts and price targets.

INTS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-01-13

1 of 1

Forecast return on equity

Is INTS forecast to generate an efficient return?

Company
-7,326.23%
Industry
140.86%
Market
89.98%
INTS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is INTS forecast to generate an efficient return on assets?

Company
-798.36%
Industry
32.43%
INTS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

INTS earnings per share forecast

What is INTS's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.24
Avg 2 year Forecast
-$1.34
Avg 3 year Forecast
-$1.48

INTS revenue forecast

What is INTS's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$1.1M
Avg 2 year Forecast
$59.4M
Avg 3 year Forecast
$97.1M

INTS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
INTS$0.32$8.50+2,572.96%Strong Buy
KTTA$0.79N/AN/A
SNGX$1.80N/AN/A
RNAZ$6.97$280.00+3,917.22%Buy
CELZ$2.18N/AN/A
View Top Biotech Stocks

Intensity Therapeutics Stock Forecast FAQ

Is Intensity Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: INTS) stock is to Strong Buy INTS stock.

Out of 1 analyst, 1 (100%) are recommending INTS as a Strong Buy, 0 (0%) are recommending INTS as a Buy, 0 (0%) are recommending INTS as a Hold, 0 (0%) are recommending INTS as a Sell, and 0 (0%) are recommending INTS as a Strong Sell.

If you're new to stock investing, here's how to buy Intensity Therapeutics stock.

What is INTS's earnings growth forecast for 2025-2027?

(NASDAQ: INTS) Intensity Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.32%.

Intensity Therapeutics's earnings in 2025 is -$15,012,000.On average, 1 Wall Street analyst forecast INTS's earnings for 2025 to be -$22,813,770, with the lowest INTS earnings forecast at -$22,813,770, and the highest INTS earnings forecast at -$22,813,770. On average, 1 Wall Street analyst forecast INTS's earnings for 2026 to be -$24,653,591, with the lowest INTS earnings forecast at -$24,653,591, and the highest INTS earnings forecast at -$24,653,591.

In 2027, INTS is forecast to generate -$27,229,339 in earnings, with the lowest earnings forecast at -$27,229,339 and the highest earnings forecast at -$27,229,339.

What is INTS's revenue growth forecast for 2027-2029?

(NASDAQ: INTS) Intensity Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.57%.

Intensity Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast INTS's revenue for 2027 to be $19,318,112, with the lowest INTS revenue forecast at $19,318,112, and the highest INTS revenue forecast at $19,318,112. On average, 2 Wall Street analysts forecast INTS's revenue for 2028 to be $1,092,853,199, with the lowest INTS revenue forecast at $155,832,771, and the highest INTS revenue forecast at $2,029,873,627.

In 2029, INTS is forecast to generate $1,786,465,414 in revenue, with the lowest revenue forecast at $260,334,558 and the highest revenue forecast at $3,312,596,270.

What is INTS's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: INTS) forecast ROA is -798.36%, which is lower than the forecast US Biotechnology industry average of 32.43%.

What is INTS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year INTS price target, the average INTS price target is $8.50, with the highest INTS stock price forecast at $8.50 and the lowest INTS stock price forecast at $8.50.

The Wall Street analyst predicted that Intensity Therapeutics's share price could reach $8.50 by Jan 13, 2026. The average Intensity Therapeutics stock price prediction forecasts a potential upside of 2,572.96% from the current INTS share price of $0.32.

What is INTS's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: INTS) Intensity Therapeutics's current Earnings Per Share (EPS) is -$1.05. On average, analysts forecast that INTS's EPS will be -$1.24 for 2025, with the lowest EPS forecast at -$1.24, and the highest EPS forecast at -$1.24. On average, analysts forecast that INTS's EPS will be -$1.34 for 2026, with the lowest EPS forecast at -$1.34, and the highest EPS forecast at -$1.34. In 2027, INTS's EPS is forecast to hit -$1.48 (min: -$1.48, max: -$1.48).

What is INTS's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: INTS) forecast ROE is -7,326.23%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.